BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation. Int J Mol Sci 2020;21:E559. [PMID: 31952316 DOI: 10.3390/ijms21020559] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Alavi SE, Esfahani MKM, Raza A, Adelnia H, Shahmabadi HE. PEG-grafted liposomes for enhanced antibacterial and antibiotic activities: An in vivo study. NanoImpact 2022. [DOI: 10.1016/j.impact.2022.100384] [Reference Citation Analysis]
2 Sun Y, Xie Y, Tang H, Ren Z, Luan X, Zhang Y, Zhu M, Lv Z, Bao H, Li Y, Liu R, Shen Y, Zheng Y, Pei J. In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer. Int J Nanomedicine 2021;16:8279-303. [PMID: 34992365 DOI: 10.2147/IJN.S340180] [Reference Citation Analysis]
3 Omabe K, Paris C, Lannes F, Taïeb D, Rocchi P. Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes. Pharmaceutics 2021;13:591. [PMID: 33919150 DOI: 10.3390/pharmaceutics13050591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mirnezami SMS, Heydarinasab A, Akbarzadeh A, Arjmand M. Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing Melphalan on ovarian cancer: an in vitro study. Journal of Experimental Nanoscience 2021;16:101-15. [DOI: 10.1080/17458080.2021.1922669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Renault-Mahieux M, Vieillard V, Seguin J, Espeau P, Le DT, Lai-Kuen R, Mignet N, Paul M, Andrieux K. Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation. Pharmaceutics 2021;13:970. [PMID: 34206986 DOI: 10.3390/pharmaceutics13070970] [Reference Citation Analysis]
6 Hussain H, Wattoo FH, Wattoo MHS, Gulfraz M, Masud T, Shah I, Ali S, Alavi SE. Camel milk as an alternative treatment regimen for diabetes therapy. Food Sci Nutr 2021;9:1347-56. [PMID: 33747450 DOI: 10.1002/fsn3.2078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Esfahani MKM, Alavi SE, Cabot PJ, Islam N, Izake EL. PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics 2021;13:1605. [PMID: 34683898 DOI: 10.3390/pharmaceutics13101605] [Reference Citation Analysis]
8 Alavi SE, Ebrahimi Shahmabadi H. GLP-1 peptide analogs for targeting pancreatic beta cells. Drug Discov Today 2021;26:1936-43. [PMID: 33839290 DOI: 10.1016/j.drudis.2021.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alavi SE, Ebrahimi Shahmabadi H. Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharm J 2021;29:434-45. [PMID: 34135669 DOI: 10.1016/j.jsps.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ghaferi M, Amari S, Mohrir BV, Raza A, Shahmabadi HE, Alavi SE. Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities. Pharmaceuticals (Basel) 2020;13:E44. [PMID: 32168743 DOI: 10.3390/ph13030044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
11 Ashrafzadeh MS, Akbarzadeh A, Heydarinasab A, Ardjmand M. In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin. Int J Nanomedicine 2020;15:7035-49. [PMID: 33061366 DOI: 10.2147/IJN.S255902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ghaferi M, Koohi Moftakhari Esfahani M, Raza A, Al Harthi S, Ebrahimi Shahmabadi H, Alavi SE. Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances. J Drug Target 2021;29:131-54. [PMID: 32815741 DOI: 10.1080/1061186X.2020.1812614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Sun M, Yuan Y, Lu F, Di Pasqua AJ. Physicochemical Factors That Influence the Biocompatibility of Cationic Liposomes and Their Ability to Deliver DNA to the Nuclei of Ovarian Cancer SK-OV-3 Cells. Materials (Basel) 2021;14:416. [PMID: 33466992 DOI: 10.3390/ma14020416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zheng Y, Xu G, Ni Q, Wang Y, Gao Q, Zhang Y. Microemulsion Delivery System Improves Cellular Uptake of Genipin and Its Protective Effect against Aβ1-42-Induced PC12 Cell Cytotoxicity. Pharmaceutics 2022;14:617. [DOI: 10.3390/pharmaceutics14030617] [Reference Citation Analysis]
15 Yousefi Aldashi S, Saffari Z, Ebrahimi Shahmabadi H, Akbarzadeh A. In Vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer. Adv Pharm Bull 2021;11:267-73. [PMID: 33880348 DOI: 10.34172/apb.2021.039] [Reference Citation Analysis]
16 Wang P, Wang JW, Zhang WH, Bai H, Tang G, Young DJ. In Vitro Anticancer Activity of Nanoformulated Mono- and Di-nuclear Pt Compounds. Chem Asian J 2021. [PMID: 34387027 DOI: 10.1002/asia.202100901] [Reference Citation Analysis]
17 Su X, Zhang X, Liu W, Yang X, An N, Yang F, Sun J, Xing Y, Shang H. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin Cancer Biol 2021:S1044-579X(21)00215-7. [PMID: 34375726 DOI: 10.1016/j.semcancer.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F. Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. J Pharm Sci 2021:S0022-3549(21)00488-3. [PMID: 34547305 DOI: 10.1016/j.xphs.2021.09.018] [Reference Citation Analysis]
19 Brummelhuis ISG, Simons M, Lindner LH, Kort S, de Jong S, Hossann M, Witjes JA, Oosterwijk E. DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo. Int J Hyperthermia 2021;38:1415-24. [PMID: 34581259 DOI: 10.1080/02656736.2021.1983038] [Reference Citation Analysis]
20 Xu J, Hu T, Zhang M, Feng P, Wang X, Cheng X, Tang R. A sequentially responsive nanogel via Pt(IV) crosslinking for overcoming GSH-mediated platinum resistance. J Colloid Interface Sci 2021;601:85-97. [PMID: 34058555 DOI: 10.1016/j.jcis.2021.05.107] [Reference Citation Analysis]
21 Moammeri A, Abbaspour K, Zafarian A, Jamshidifar E, Motasadizadeh H, Dabbagh Moghaddam F, Salehi Z, Makvandi P, Dinarvand R. pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Tumorigenesis Breast Cancer. ACS Appl Bio Mater 2022. [PMID: 35129960 DOI: 10.1021/acsabm.1c01107] [Reference Citation Analysis]
22 Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Yasir M, Ghoneim MM, Alshehri S, Anwer MK, Almurshedi AS, Alanazi AS. Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study. Drug Deliv 2021;28:2562-73. [PMID: 34866534 DOI: 10.1080/10717544.2021.2008055] [Reference Citation Analysis]
23 Esfahani MKM, Islam N, Cabot PJ, Izake EL. Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy. ACS Biomater Sci Eng 2021. [PMID: 34056895 DOI: 10.1021/acsbiomaterials.1c00066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]